Angiogenesis: A curse or cure?

Postgraduate Medical Journal

Volumn 81, Issue 954, 2005, Pages 236-242

  Gupta, K ^a   Zhang, J ^b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOZYME; BECAPLERMIN; BEVACIZUMAB; CELECOXIB; CELL CYCLE PROTEIN; CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; ENDOSTATIN; ENMD 0996; EPHRIN; ESTRADIOL; FIBROBLAST GROWTH FACTOR; FOLLISTATIN; GROWTH FACTOR; HYDROMORPHONE; HYPOXIA INDUCIBLE FACTOR 1; IMATINIB; IMC 1121NB; INTEGRIN; INTERLEUKIN 8; LEPTIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MORPHINE; PIGMENT EPITHELIUM DERIVED FACTOR; PLACENTAL GROWTH FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLEIOTROPHIN; PRINOMASTAT; PROLIFERIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; REBIMASTAT; SCATTER FACTOR; SEMAXANIB; SUNITINIB; TANOMASTAT; THALIDOMIDE; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; VITRONECTIN RECEPTOR; ZK 225;

ANGIOGENESIS; BASEMENT MEMBRANE; BLEEDING; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC FOOT; EXTRACELLULAR MATRIX; FETUS DEVELOPMENT; GENE THERAPY; HUMAN; HYPERTENSION; LEG ULCER; METASTASIS; NONHUMAN; OVARY CYCLE; PROTEINURIA; RETINOPATHY; REVIEW; THROMBOSIS; TISSUE REPAIR; VASCULAR ENDOTHELIUM; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ENDOTHELIAL CELLS; GROWTH SUBSTANCES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RETINAL VESSELS; STEM CELL TRANSPLANTATION;

EID: 17444374974     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.023309     Document Type: Review

References (61)

1. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
3. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
4. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954-8.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
6. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358-66.
7. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000;11:617-24.
8. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
9. Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-35.
10. Isner JM. Myocardial gene therapy. Nature 2002;415:234-9.
11. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
12. Gupta K, Gupta P, Wild R, et al. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999;3:147-58.
13. Becerra S, Sagasti A, Spinella P. Pigment epithelium-derived factor behaves like a noninhibitory serpin: Neurotrophic activity does not require the serpin reactive loop. J Biol Chem 1995;270:25992-9.
14. Doll JA, Stellmach VM, Bouck NP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003;9:774-80.
15. Wang L, Schmitz V, Perez-Mediavilla A, et al. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003;8:72-9.
16. Zhang J, Shen KW, Liu G, et al. Antigenic profiles of disseminated breast tumour cells and microenvironment in bone marrow. Eur J Surg Oncol 2003;29:121-6.
17. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003;22:6549-56.
18. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(suppl 16):15-18.
19. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991;51(suppl 18):5054-9s.
20. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 2004;101:591-6.
21. Ruzinova MB, Schoer RA, Gerald W, et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003;4:277-89.
22. Zhang F, Cheng J, Hackett NR, et al. Adenovirus E4 gene promotes selective endothelial cell survival and angiogenesis vio activation of the VE-cadherin/ Akt signaling pathway. J Biol Chem 2004;279:11760-6.
23. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-27.
24. Bainbridge JW, Mistry AR, Thrasher AJ, et al. Gene therapy for ocular angiogenesis. Clin Sci (Lond) 2003;104:561-75.
25. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings, DRS Report Number 8. Ophthalmology 1981;88:583-600.
26. Aiello LP, Cahill MT, Cavallerano JD. Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopothy. Eye 2004;18:117-25.
27. Zwaginga JJ, Doevendans. Stem cell-derived angiogenic/vasculogenic cells: possible therapies for tissue repoir and tissue engineering. Clin Exp Pharmacol Physiol 2003;30:900-8.
28. Tepper OM, Sealove BA, Murayama T, et al. Newly emerging concepts in blood vessel growth: recent discovery of endothelial progenitor cells and their function in tissue regeneration. J Investig Med 2003;51:353-9.
29. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9:702-12.
30. Matsumoto K, Yoshitomi H, Rossant J, et al. Liver organogenesis promoted by endothelial cells prior to vascular function. Science 2001;294:559-63.
31. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004;10:64-71.
32. Koike N, Fukumura D, Gralla O, et al. Tissue engineering: creation of long-lasting blood vessels. Nature 2004;428:138-9.
33. Kirchner LM, Meerbaum SO, Gruber BS, et al. Effects of vascular endothelial growth factor on wound closure rates in the genetically diabetic mouse model. Wound Repair Regen 2003;11:127-31.
34. Galiano RD, Tepper OM, Pelo CR, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004;164:1935-47.
35. Angiogenesis Research Library, http://www.angio.org/researcher/library/ library.html.
36. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Cancer Rev 2002;2:727-39.
37. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275:1209-15.
38. Maeshima Y, Manfredi M, Reimer C, et al. Identification of the antiangiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001;276:15240-8.
39. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002;295:140-3.
40. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin Cancer Res, 2000;6:3056-61.
41. Fabbro D, Parkinson D, Matter A. Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol 2002;2:374-81.
42. Savage DG, Antman KG. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002;346:683-93.
43. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (FCR/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
44. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
45. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
46. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: Meeting overview. Cancer Res 2003;63:1144-7.
47. Eberhard A, Haklert S, Groede V, et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93.
48. Fidler U, Ellis LM. Neoplastic angiogenesis. N Engl J Med 2004;351:215-16.
49. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003;100:12917-22.
50. Zondor SD, Medina PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pnarmacol 2004;38:1258-64.
51. Takeuchi Y, Kurohane K, Ichikawa K, et al. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer 2003;97:2027-34.
52. Le Gat L, Gogat K, Bouquet C, et al. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopothy. Gene Ther 2003;10:2098-103.
53. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
54. Nwogu JI, Geenen D, Bean M, et al. Inhibition of collagen synthesis with prolyl 4- hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 2001;104:2216-21.
55. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002;62:4491-8.
56. Ishikawa M, Tanno K, Kamo A, et al. Enhancement of tumor growth by morphine and its possible mechanism in mice. Biol Pharm Bull 1993;16:762-6.
57. Poonawala T, Levay-Young BK, Hebbel RP, et al. Opioids heal ischemic wounds in rats. Wound Repair and Regeneration 2005;13:165-74.
58. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
59. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the anti-tumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
60. Tarkka T, Sipola A, Jamsa T, et al. Adenoviral VEGF-A gene transfer induces angiogenesis and promotes bone formation in healing osseous tissues. J Gene Med 2003;5:560-6.
61. Hong Y-K, Lange-Asschenfeldt B, Velasco P, et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the α1β1 and α2β1 integrins. FASEB J 2004;Express article 10.1046/fj.03-1179fje.